Popular breast cancer drugs don't work the way we thought they did

New research suggests that a class of drugs called PARP inhibitors, designed to treat hereditary forms of ovarian and breast cancer, don't work the way we thought they did. It also paints a fuller picture of how they work, opening the door to improvements in next-generation drugs.

source https://www.sciencedaily.com/releases/2021/02/210203144547.htm